Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW to Set Up MID-NET Usage Fees to Induce Drug Makers to Use It for PMS: Official
The Ministry of Health, Labor and Welfare (MHLW) will set appropriate usage fees for its large-scale medical information database, dubbed MID-NET, in order to induce drug makers to use it as an alternative means of post-marketing surveillance (PMS), an official…
To read the full story
Related Article
- Final Report on MID-NET’s Full Operations Published
August 22, 2017
- Panel OKs 42.12 Million Yen Price Tag for Drug Makers’ MID-NET Use in PMS
July 20, 2017
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
- No Extra Fees Will Be Charged for Add’l Survey Items for MID-NET’s PMS Use: MHLW Working Group
March 23, 2017
- MID-NET Working Group Agrees on Flat Access Fees for Drug Makers’ PMS Use
November 30, 2016
- MID-NET Working Group Discusses Access Fee Calculations
October 28, 2016
- MID-NET Working Group Kicks Off Discussions on Access Fees
September 30, 2016
REGULATORY
- Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models
April 16, 2026
- MHLW to Set Criteria for Exemptions under OTC-Like Drug Charge Scheme
April 16, 2026
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…